- Home
- SRPT
as 12-18-2024 12:43pm EST
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 12.2B | IPO Year: | 1997 |
| Target Price: | $179.38 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $89.92 - $173.25 | Next Earning Date: | 11-06-2024 |
| Revenue: | $1,640,348,000 | Revenue Growth: | 48.45% |
| Revenue Growth (this year): | 50.4% | Revenue Growth (next year): | 71.44% |
Stock Insider Trading Activity of Sarepta Therapeutics Inc. (DE) (SRPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wigzell Hans Lennart Rudolf | SRPT | Director | Dec 12 '24 | Sell | $124.84 | 10,500 | $1,310,820.00 | 22,840 |
Latest Sarepta Therapeutics Inc. (DE) News
SRPT Breaking Stock News: Dive into SRPT Ticker-Specific Updates for Smart Investing
Business Wire
5 hours ago
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Zacks
a day ago
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
MT Newswires
a day ago
Sarepta Therapeutics Insider Sold Shares Worth $1,310,820, According to a Recent SEC Filing
Insider Monkey
4 days ago
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
Zacks
5 days ago
Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?
Argus Research
8 days ago
SRPT: What does Argus have to say about SRPT?
Zacks
12 days ago
Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report?
Argus Research
15 days ago
SRPT: Lowering target price to $101.00
Compare SRPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRPT Sarepta Therapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.